Antidepressants in Japan

From WikiMD's Medical Encyclopedia

Revision as of 13:18, 8 March 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Antidepressants in Japan are a class of medications used primarily to treat depression, but also for other mental health conditions. In Japan, the use of antidepressants has been influenced by cultural, societal, and medical factors unique to the country.

History[edit]

The history of antidepressants in Japan is marked by a late introduction compared to Western countries. The first antidepressant, iproniazid, was not introduced until 1958, several years after its introduction in the United States. This delay was due to a variety of factors, including societal stigma towards mental health disorders and a lack of understanding about the biological basis of depression.

Usage[edit]

The usage of antidepressants in Japan has increased significantly over the past few decades. This is due in part to a shift in societal attitudes towards mental health, as well as changes in the Japanese healthcare system that have made it easier for individuals to seek treatment for mental health disorders. Despite this increase, the usage of antidepressants in Japan remains lower than in many Western countries.

Types of Antidepressants[edit]

There are several types of antidepressants available in Japan, including Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), and Tricyclic antidepressants (TCAs). Each of these types of antidepressants works in a slightly different way to alleviate the symptoms of depression.

Cultural and Societal Factors[edit]

Cultural and societal factors have played a significant role in the use of antidepressants in Japan. Historically, there has been a strong stigma associated with mental health disorders in Japan, which has made it difficult for individuals to seek treatment. However, this stigma has been gradually decreasing, leading to an increase in the use of antidepressants.

Regulation[edit]

The regulation of antidepressants in Japan is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA). The PMDA is responsible for ensuring the safety and efficacy of all medications sold in Japan, including antidepressants.

See Also[edit]

References[edit]

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.